Pharmabiz4h
Vitonnix UK joins SEARCH Foundation in its mission to target the vitamin D deficiency endemic in rural India
Our Bureau, Mumbai Wednesday, November 13, 2024, 12:15 Hrs [IST] ...
Pharmabiz59m
Sonoma Pharma receives US FDA 510(k) clearance for Microcyn-based wound care hydrogel
Sonoma Pharma receives US FDA 510(k) clearance for Microcyn-based wound care hydrogel: Boulder, Colorado Wednesday, November 13, 2024, 16:00 Hrs [IST] Sonoma Pharmaceuticals, Inc.
Pharmabiz17h
Oncoinvent announces positive interim results from phase 1/2a studies of Radspherin for treatment of peritoneal carcinomatosis
Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, announced an interim data readout of the phase 1/2a studies of Radspherin for the treatment ...
Pharmabiz1h
Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia
Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...
Pharmabiz29m
Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury
Arch Biopartners Inc, a late-stage clinical trial company focused on preventing inflammation and acute organ injury, has announced that patient recruitment and dosing have begun in Canada for the ...
Pharmabiz1h
KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1
KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...
Pharmabiz2h
US FDA grants breakthrough therapy designation to Johnson & Johnson’s nipocalimab to treat adults living with moderate-to-severe Sjögren's disease
Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...
Pharmabiz1h
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC
AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients ...
Pharmabiz22h
Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced ...
Pharmabiz23h
ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions
ALK, a global specialty pharmaceutical company focused on allergy and allergic asthma, announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (ARS ...
Pharmabiz3h
Merck to present new data from Gardasil 9 studies reinforcing the importance of gender-neutral HPV vaccination in adults up to age 45 at IPVC 2024
Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...
Pharmabiz7h
AstraZeneca to invest $3.5 billion in R&D and manufacturing in US
AstraZeneca to invest $3.5 billion in R&D and manufacturing in US: Cambridge, UK Wednesday, November 13, 2024, 09:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceutical ...